MA38056A1 - Inhibitors of crude tyrosine kinase - Google Patents

Inhibitors of crude tyrosine kinase

Info

Publication number
MA38056A1
MA38056A1 MA38056A MA38056A MA38056A1 MA 38056 A1 MA38056 A1 MA 38056A1 MA 38056 A MA38056 A MA 38056A MA 38056 A MA38056 A MA 38056A MA 38056 A1 MA38056 A1 MA 38056A1
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
inhibitors
compounds
conditions
relates
Prior art date
Application number
MA38056A
Other languages
French (fr)
Other versions
MA38056B1 (en
Inventor
John Robert Springer
Balekudru Devadas
Danny James Garland
Margaret Lanahan Grapperhaus
Seungil Han
Susan Landis Hockerman
Robert Owen Hughes
Eddine Saiah
Mark Edward Schnute
Shaun Raj Selness
Daniel Patrick Walker
Zhao-Kui Wan
Li Xing
Christoph Wolfgang Zapf
Michelle Schmidt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from PCT/IB2013/059846 external-priority patent/WO2014068527A1/en
Publication of MA38056A1 publication Critical patent/MA38056A1/en
Publication of MA38056B1 publication Critical patent/MA38056B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés qui forment des liaisons covalentes avec la tyrosine kinase de bruton (btk). L'invention concerne en outre des procédés de préparation des composés. L'invention concerne également des compositions pharmaceutiques qui comprennent les composés. L'invention concerne de plus des procédés d'utilisation des inhibiteurs btk, seuls ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou d'états auto-immuns, de maladies ou d'états hétéro-immuns, de cancer, comprenant le lymphome, et de maladies ou d'états inflammatoires. (formule i) (i)The present invention relates to compounds that form covalent bonds with the bromine tyrosine kinase (btk). The invention further relates to methods of preparing the compounds. The invention also relates to pharmaceutical compositions which comprise the compounds. The invention further relates to methods of using the btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, diseases or heteroimmune conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (formula i) (i)

MA38056A 2012-11-02 2013-11-01 Inhibitors of crude tyrosine kinase MA38056B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
PCT/IB2013/059846 WO2014068527A1 (en) 2012-11-02 2013-11-01 Bruton's tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
MA38056A1 true MA38056A1 (en) 2018-01-31
MA38056B1 MA38056B1 (en) 2018-08-31

Family

ID=55700669

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38056A MA38056B1 (en) 2012-11-02 2013-11-01 Inhibitors of crude tyrosine kinase

Country Status (2)

Country Link
MA (1) MA38056B1 (en)
UA (1) UA110910C2 (en)

Also Published As

Publication number Publication date
UA110910C2 (en) 2016-02-25
MA38056B1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
TN2015000168A1 (en) INHIBITORS OF BRUTON TYROSINE KINASE
MA38183A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MA38961A1 (en) 3-phenyl-1h-pyrazolo [3,4-d] pyrimidin-4-ylamine compounds substituted for the crude tyrosine kinase inhibitors used to treat, for example, autoimmune, respiratory and inflammatory diseases, cancer, mastocytosis and osteoporosis
MA41179A (en) PARG INHIBITOR COMPOUNDS
MA32226B1 (en) Compositions and their methods of preparation and use
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MA47356B1 (en) Isochromene derivatives useful as inhibitors of phosphoinositide 3-kinases
TN2014000420A1 (en) INDOLE AND INDAZOLE DERIVATIVES THAT ACTIVATE MPK
MA38391A1 (en) Pyridinyl and triazolone pyridinyl derivatives of fusion
MA33606B1 (en) PYRIMIDINE DERIVATIVES AS TYROSINE KINASE 2 PROTEIN INHIBITORS
BR112014026703A2 (en) dna-pk inhibitors
EA201300246A1 (en) BLUTON TYROSINKINASE INHIBITORS
MA39211A1 (en) Tricyclic compounds as anti-cancer agents
MA37711A1 (en) Crystalline forms of a crude tyrosine kinase inhibitor
MA33566B1 (en) THIOHYDANTOIDS (HETEROARYLMETHYL) SUBSTITUTED AS ANTICANCER DRUGS
MA37829A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an inhibitor of egfr and optionally a pi3k alpha inhibitor
MA38349A1 (en) Estra-1,3,5 (10), 16-tetraeno-3-carboxamide to inhibit 17-beta-hydroxysteroid dehydrogenase (akr1c3)
MA37742B1 (en) Derivatives of 3-substituted oestra-1,3,5 (10), 16-tetraene, processes for their preparation, pharmaceutical preparations containing them, and their use in the manufacture of medicaments
MA38315A1 (en) Heterocycle-substituted tetracyclic compounds and methods for their use in the treatment of viral diseases
MA35895B1 (en) Iap inhibitors
MA38925A1 (en) Substituted phenylalanine derivatives
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MA35064B1 (en) THIENO [2,3-D] PYRIMIDINE DERIVATIVES AND THEIR USE FOR TREATING ARRHYTHMIA
MA38056B1 (en) Inhibitors of crude tyrosine kinase
MA33938B1 (en) 5-alkynyl-PYRIMIDINE